Hernexeos (zongertinib) — Highmark
unresectable or metastatic non-squamous non–small cell lung cancer harboring HER2 (ERBB2) tyrosine kinase domain activating mutations
Initial criteria
- age ≥ 18 years
- diagnosis of unresectable or metastatic non-squamous non-small cell lung cancer (ICD-10: C34.90)
- disease harbors HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-approved test
- member has received prior systemic therapy
Reauthorization criteria
- prescriber attests that the member is tolerating therapy
- member has experienced a therapeutic response defined as disease improvement OR delayed disease progression
Approval duration
12 months